A 28-year-old woman with mild persistent asthma presents for routine follow-up. She experiences symptoms 3–4 times per week and uses her salbutamol inhaler 2–3 times weekly. She has no nocturnal symptoms. What is the drug of choice for long-term control in this patient?

Explanation

## Classification of Asthma Severity and Control Mild persistent asthma is defined by symptoms 3–6 days per week and nighttime awakenings 1–3 times per month. This patient requires step-2 therapy (long-term control medication). ### Step-2 Therapy: First-Line Agent **Key Point:** Inhaled corticosteroids (ICS) are the most effective and preferred first-line controller medication for all levels of persistent asthma, including mild persistent. **High-Yield:** ICS are superior to all other monotherapy options (LABA, LTRA, theophylline) in reducing airway inflammation, improving lung function, and preventing exacerbations [cite:GINA 2023]. ### Why Low-Dose ICS? | Feature | Low-Dose ICS | LABA Monotherapy | LTRA Monotherapy | |---------|-------------|-----------------|------------------| | **Efficacy in mild persistent** | Excellent | Inferior; risk of severe exacerbation | Modest; less effective than ICS | | **Anti-inflammatory action** | Direct suppression of airway inflammation | Bronchodilation only; no anti-inflammatory effect | Modest anti-inflammatory; weaker than ICS | | **Exacerbation prevention** | Proven | Increased risk if used alone | Moderate reduction | | **Systemic side effects (low-dose)** | Minimal | Tremor, tachycardia | Rare | **Clinical Pearl:** LABA monotherapy is contraindicated in asthma because it increases the risk of severe exacerbations and asthma-related deaths when used without concurrent ICS. **Mnemonic:** **STEP-2 = ICS** — Any persistent asthma (mild, moderate, or severe) starts with an inhaled corticosteroid as the backbone of therapy. ### Dosing in Mild Persistent Asthma - **Beclomethasone:** 40–80 mcg twice daily - **Fluticasone propionate:** 44–88 mcg twice daily - **Budesonide:** 80–160 mcg twice daily **Tip:** Reassess control in 2–4 weeks. If well-controlled on low-dose ICS, continue. If inadequately controlled, step up to ICS + LABA combination (step 3).